‚ÄčThis webinar was co-sponsored by the QA/QC Subcommittee of the APHL Newborn Screening and Genetics in Public Health Committee and the Newborn Screening Quality Assurance Program (NSQAP) at CDC. The webinar gave a historical overview of mass spectrometry in newborn screening, reviewed the NSQAP method performance data for selected analytes and discussed the factors that should be considered in making the decision whether to switch to a non-derivatized method through case studies of two states that switched and two states that have not. 

This page links to presentations that have been authorized for posting on this site. Duplication is not authorized without the express written permission of the authors.

Webinar Presentation in Full with Audio and Presentations

Wednesday, May 30

Newborn Screening by Tandem Mass Spectrometry (MS/MS): State Experiences and Considerations with Derivatized and Non-Derivatized Methods
-Art Hagar, Georgia Public Health Laboratory

The Historical and Present Day Basis for the Derivatization in the MS/MS Analysis of DBS in Newborn Screening
-Donald Chace, Pediatrix Medical Group

Assuring the Quality of MS/MS Dried Blood Spot Newborn Screening Testing
- Victor De Jesus, CDC

Newborn Screening by Tandem Mass Spectrometry in Texas
- Patricia R. Hunt, Texas Department of State Health Services

Newborn Screening by Tandem Mass Spectrometry in California
-Fred Lorey, California Department of Public Health Laboratory

Evaluation of the Neobase Non-derivatized Kit in the Missouri Newborn Screening Laboratory
-Patrick Hopkins, Missouri State Public Health Laboratory

MS/MS Screening: To "D" or Not to "D", That is the Question
-Mike Glass and Bill Hoffman, Washington Public Health Laboratory.